Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients
Éveline Boucher(Boston Scientific (United States)), Yves Deugnier(Inserm), Patrice André, M. Messner(Inserm), Sylvie Jacquelinet(Inserm), P. Gasser(Hôpital Laennec), Bruno Turlin(Inserm), Pierre–Henri Bernard(Hôpital Saint-André), O Nouël(Centre Hospitalier de Saint-Brieuc), F Joram(Centre Hospitalier Avranches Granville), Julian Boutin(Université de Bordeaux), P. Bergerault(Centre hospitalier Bretagne Atlantique), Pierre Brissot(Inserm), Dominique Guyader(Inserm), V. Canva(Hôpital Claude Huriez), Thông Dao(Centre Hospitalier Universitaire de Caen Normandie), J.-J. Raabe(Centre Hospitalier Régional de Metz-Thionville), Michel Mendler(Inserm), P. Colmar, J.‐B. Nousbaum(Hôpital Maison Blanche), P Verger
Cited by 11
Related Papers
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload
|Journal of Biological Chemistry|2001|1.7k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study
|Journal of Clinical Oncology|2013|596
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
|Molecular Pharmacology|1993|536